Detalhe da pesquisa
1.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914339
2.
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).
Oncologist
; 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445723
3.
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Breast Cancer Res Treat
; 194(1): 1-11, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35587323
4.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112166
5.
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Breast Cancer Res Treat
; 188(2): 477-487, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852121
6.
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
Cancer
; 126(24): 5239-5246, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32931029
7.
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Breast Cancer Res Treat
; 182(3): 613-622, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32504284
8.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Cancer
; 125(22): 3974-3984, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318460
9.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 620, 2019 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31234810
10.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 517, 2019 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146717
11.
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Value Health
; 22(4): 408-415, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30975391
12.
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Breast Cancer Res
; 20(1): 52, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898752
13.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med
; 373(21): 2005-14, 2015 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412349
14.
Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.
Pharmacogenet Genomics
; 27(10): 378-385, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28763429
15.
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Oncologist
; 22(10): 1160-1168, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592618
16.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881463
17.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat
; 165(2): 329-341, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28612225
18.
Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
Drug Resist Updat
; 24: 13-22, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26830312
19.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 17(6): 811-821, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27155741
20.
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Breast Cancer Res
; 18(1): 126, 2016 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27955684